Metagenomi Therapeutics (MGX) vs Veru (VERU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Veru (VERU) has outperformed Metagenomi Therapeutics (MGX) over the past year, losing 45.1% versus a loss of 68.9%. Veru is the larger company by market cap ($41.3 million vs $37.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGX | VERU |
|---|---|---|
| Share price | $0.9932 | $2.42 |
| Market cap | $37.52M | $41.26M |
| 1-day change | +0.86% | -1.63% |
| YTD return | -38.69% | +13.08% |
| 1-year return | -68.87% | -45.12% |
| 5-year return | — | -97.18% |
| EPS (TTM) | $-2.49 | $-0.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.95 | $7.33 |
| 52-week low | $0.96 | $2.05 |
| Distance from 52-week high | -74.86% | -66.98% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +604.79% | +960.74% |
| Average volume | 158.27K | 242.06K |
| Shares outstanding | 37.78M | 17.05M |
| Employees | 113 | 20 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VERU has outperformed MGX by 23.7 percentage points over the past year.
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Healthcare · Biotechnology · 113 employees
About Veru
VERU stock →Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Healthcare · Biotechnology · 20 employees
MGX vs VERU FAQ
Which is bigger, Metagenomi Therapeutics or Veru?
Veru (VERU) is larger, with a market capitalization of $41.26M compared with $37.52M for Metagenomi Therapeutics (MGX).
Which stock has performed better over the past year, MGX or VERU?
VERU returned -45.12% over the past 12 months, compared with -68.87% for MGX (price return, excluding dividends). Past performance does not predict future results.
Are Metagenomi Therapeutics and Veru in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.